Early Cell Fate Decisions of Human Embryonic Stem Cells and Mouse Epiblast Stem Cells Are Controlled by the Same Signalling Pathways
Ludovic Vallier, Thomas Touboul, Zhenzhi Chng et al. · 2009
Read Early Cell Fate Decisions of Human Embryonic Stem Cells and Mouse Epiblast Stem Cells Are Controlled by the Same Signalling Pathways by Ludovic Vallier, Thomas Touboul, Zhenzhi Chng et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0006082.txt.
Introduction
Stem cells from a human embryo and from a mouse's early lining look different, yet may obey the same rules. Ludovic Vallier, Thomas Touboul, Zhenzhi Chng and colleagues tested that in 2009. Their PLOS ONE paper compares early cell fate decisions in human embryonic stem cells and mouse epiblast stem cells, the choices that start the making of body tissues.
The same signaling pathways control those first choices in both, the title reports. Shared rules mean mouse findings can guide human stem cell work with more confidence. That matters for regenerative medicine, where steering stem cells into the right tissue is the whole craft, and where human cells are costly to test directly.
Catalog record
| CREATOR | Ludovic Vallier, Thomas Touboul, Zhenzhi Chng et al. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0006082
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Early Cell Fate Decisions of Human Embryonic Stem Cells and Mouse Epiblast Stem Cells Are Controlled by the Same Signalling Pathways Authors: Ludovic Vallier, Thomas Touboul, Zhenzhi Chng, Minodora Brimpari, Nicholas Hannan, Enrique Millan, Lucy E. Smithers, Matthew Trotter, Peter Rugg-Gunn, Anne Weber, Roger A. Pedersen Published: 2009, PLOS ONE DOI: 10.1371/journal.pone.0006082 ABSTRACT Human embryonic stem cells have unique value for regenerative medicine, as they are capable of differentiating into a broad variety of cell types. Therefore, defining the signalling pathways that control early cell fate decisions of pluripotent stem cells represents a major task. Moreover, modelling the early steps of embryonic development in vitro may provide the best approach to produce cell types with native properties. Here, we analysed the function of key developmental growth factors such as Activin, FGF and BMP in the control of early cell fate decisions of human pluripotent stem cells. This analysis resulted in the development and validation of chemically defined culture conditions for achieving specification of human embryonic stem cells into neuroectoderm, mesendoderm and into extra-embryonic tissues. Importantly, these defined culture conditions are devoid of factors that could obscure analysis of developmental mechanisms or render the resulting tissues incompatible with future clinical applications. Importantly, the growth factor roles defined using these culture conditions similarly drove differentiation of mouse epiblast stem cells derived from post implantation embryos, thereby reinforcing the hypothesis that epiblast stem cells share a common embryonic identity with human pluripotent stem cells. Therefore the defined growth factor conditions described here represent an essential step toward the production of mature cell types from pluripotent stem cells in conditions fully compatible with clinical use ant also provide a general approach for modelling the early steps of mammalian embryonic development. INTRODUCTION Human Embryonic Stem cells (hESCs) are pluripotent cells cultured from embryos at the blastocyst stage [1] . Their pluripotent status confers upon them the capacity to differentiate into a wide variety of cell types. However, generating fully functional cells from hESCs and achieving this goal using clinically-compatible conditions remain major challenges owing to the presence of undefined serum and cellular components in standard culture media and differentiation protocols. Indeed, widely-used methods are based on media formulations containing unknown factors and animal derived products in addition to serum such as Matrigel, and stroma cells [2] , [3] . While modelling the early steps of embryonic development in vitro may provide the best approach for generating differentiated cells with native properties, devising protocols for differentiation of pluripotent stem cells is largely an empirical task. The earliest cell fate decisions during mammalian embryonic development are the specification of extra-embryonic tissues, starting with the trophectoderm and the primitive endoderm. Differentiation of definitive embryonic tissues occurs later, at the gastrulation stage, with the specification of the ectoderm, mesoderm and endoderm germ layers from which all the adult tissues are derived. Here, we analysed the effect of key developmental signalling pathways such as Activin/Nodal, FGF and BMP4 on early cell fate decisions of hESCs using an approach based on a fully chemically defined medium. This is resulted in the definition of the function of each pathway in the specification of extra-embryonic tissues and the primary germ layers. Based on these results, we developed and validated chemically defined culture conditions for achieving specification of hESCs into neuroectoderm and mesendoderm and into extra-embryonic tissues. Importantly, these culture conditions worked equally well to promote similar differentiation of epiblast stem cells (EpiSCs) derived from post-implantation mouse embryos [4] , [5] , although their effectiveness on mouse Embryonic Stem Cells (mESCs) was limited. Together, these results show that pluripotent mammalian stem cells can be induced to undergo early cell fate decisions in chemically defined medium supplemented with a minimal set of growth factors, thereby providing a general approach for modelling the transition between the pluripotent state and specification of the three germ layers during mammalian gastrulation. Finally, these defined culture conditions are devoid of animal products, thus they also represent a major step toward the generation of fully functional cell types compatible with future clinical applications. RESULTS The function of Activin/Nodal, FGF, Wnt and BMP signalling pathways in the differentiation of the primary germ layers is highly conserved between amphibia [6] , fish [7] and mammals [8] . Consequently, these growth factors appeared to be the best candidates to drive differentiation of hESCs. Accordingly, we undertook a systematic analysis of the effects of these four factors on hESC differentiation into neuroectoderm and mesendoderm in the absence of feeders cells, using a chemically defined medium (CDM) [9] . CDM is devoid of serum and is supplemented with insulin, transferrin and defined lipids to which was added either serum albumin or Polyvinyl Alcohol (PVA). The effect of inhibiting the Activin, FGF and PI-3-kinase signalling pathways was analysed in these conditions using respectively SB431542 [10] , a pharmacological inhibitor of Activin/Nodal receptors, SU5402 [11] , an inhibitor of FGF receptors, or LY294002 an inhibitor of PI-3-Kinase [12] . Briefly, H9 and hSF-6 hESC lines grown in CDM (containing bovine or human serum albumin) supplemented with Activin (10 ng/ml) and FGF (12 ng/ml) were plated on plastic dishes pre-coated with human fibronectin [13] . After 48 hours, Activin and FGF were replaced by other growth factors and inhibitors for varying periods. Expression of the pluripotency marker Oct-4, the pluripotency and neuroectoderm progenitor marker Sox2, the mesoderm marker Brachyury, and the endoderm marker Sox17 was analysed using immunostaining after 7 or 10 days of treatment ( Tables 1 and 2 ). This approach enabled a rapid semiquantitative assessment of the combinational options involving the four growth factor pathways. H9 hESCs were grown for different periods in CDM-BSA supplemented with different growth factors (Activin, FGF2 or BMP4) or chemical inhibitors [SB431542 (SB) for Activin/Nodal, SU5402 (SU) for FGF or BIO for GSK3β/Wnt]. Then, immunostaining analyses were used to determine the fraction of cells expressing the pluripotency marker Oct-4, the neuroectoderm marker Sox2, the mesoderm marker Brachyury, and the endoderm marker Sox17. The levels of marker-expressing cells were divided into five arbitrary categories: 0 for absence of expression, Very Low (VL) for <1% expressing cells, Low (L) for <5% expressing cells, Moderate (M) for >10% expressing cells, High (H) for >50% expressing cells. Indicated in blue are conditions allowing the generation of neuroectoderm (expressing Sox2) and in red those inducing mesendoderm (cells expressing Brachyury or Sox17). H9 hESCs were grown for different periods in CDM-PVA supplemented with different growth factors (Activin, FGF2 or BMP4) or chemical inhibitors SU5402 (SU) for FGF. Then, immunostaining analyses were used to determine the fraction of cells expressing the pluripotency marker Oct-4, the neuroectoderm marker Sox2, the mesoderm marker Brachyury, and the endoderm marker Sox17. The levels of marker-expressing cells were divided into five arbitrary categories: 0 for absence of expression, Very Low (VL) for <1% expressing cells, Low (L) for <5% expressing cells, Moderate (M) for >10% expressing cells, High (H) for >50% expressing cells. Indicated in blue are conditions allowing the generation of neuroectoderm (expressing Sox2) and in red those inducing mesendoderm (cells expressing Brachyury or Sox17). TABLE: Identification of culture conditions for inducing neuroectoderm and mesendoderm differentiation in CDM-BSA. Conditions CDM Pluripotency Neuro Meso Endo 0ct4 Sox2 Brachyury Sox17 0 L H VL